METTL3 promotes Non-Small-Cell Lung Cancer Growth and Metastasis by Inhibiting FDX1 Through Copper Death-Associated Pri-miR-21-5p Maturation

References

• Bade BC , DelaCruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin. Chest Med.41(1), 1–24 (2020).
   PubMed Web of Science ®Google Scholar
• Suster DI , Mino-KenudsonM. Molecular pathology of primary non-small cell lung cancer. Arch. Med. Res.51(8), 784–798 (2020).
   PubMed Web of Science ®Google Scholar
• Flores R , PatelP, AlpertN, PyensonB, TaioliE. Association of stage shift and population mortality among patients with non-small cell lung cancer. JAMA Netw. Open4(12), e2137508 (2021).
   PubMed Web of Science ®Google Scholar
• Wadowska K , Bil-LulaI, TrembeckiL, Sliwinska-MossonM. Genetic markers in lung cancer diagnosis: a review. Int. J. Mol. Sci.21(13), 4569 (2020).
   PubMed Web of Science ®Google Scholar
• Zhong S , GolponH, ZardoP, BorlakJ. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl. Res.230, 164–196 (2021).
   PubMed Web of Science ®Google Scholar
• Cao X , ZhongW, GuoS, ZhangZ, XieC. Low expression of miR-27b in serum exosomes of non-small cell lung cancer facilitates its progression by affecting EGFR. Open Med. (Wars.)17(1), 816–825 (2022).
   PubMedGoogle Scholar
• Friedlaender A , AddeoA, RussoA, GregorcV, CortinovisD, RolfoCD. Targeted therapies in early stage NSCLC: hype or hope?Int. J. Mol. Sci.21(17), 6329 (2020).
   PubMed Web of Science ®Google Scholar
• Jonna S , SubramaniamDS. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov. Med.27(148), 167–170 (2019).
   PubMed Web of Science ®Google Scholar
• Reck M , RemonJ, HellmannMD. First-line immunotherapy for non-small-cell lung cancer. J. Clin. Oncol.40(6), 586–597 (2022).
   PubMed Web of Science ®Google Scholar
• Chen T , NingJ, CampisiAet al. Neoadjuvant PD-1 inhibitors and chemotherapy for locally advanced NSCLC: a retrospective study. Ann. Thorac. Surg.113(3), 993–999 (2022).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Abreu D , PowellSF, HochmairMJet al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann. Oncol.32(7), 881–895 (2021).
   PubMed Web of Science ®Google Scholar
• Lin S , ChoeJ, DuP, TribouletR, GregoryRI. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol. Cell62(3), 335–345 (2016).
   PubMed Web of Science ®Google Scholar
• Maldonado Lopez A , CapellBC. The METTL3-m(6)A epitranscriptome: dynamic regulator of epithelial development, differentiation, and cancer. Genes (Basel)12(7), 1019 (2021).
   PubMed Web of Science ®Google Scholar
• Jin D , GuoJ, WuYet al. m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J. Hematol. Oncol.12(1), 135 (2019).
   PubMed Web of Science ®Google Scholar
• Wanna-Udom S , TerashimaM, LyuHet al. The m6A methyltransferase METTL3 contributes to transforming growth factor-beta-induced epithelial–mesenchymal transition of lung cancer cells through the regulation of JUNB. Biochem. Biophys. Res. Commun.524(1), 150–155 (2020).
   PubMed Web of Science ®Google Scholar
• Cai K , TonelliM, FrederickRO, MarkleyJL. Human mitochondrial ferredoxin 1 (FDX1) and ferredoxin 2 (FDX2) both bind cysteine desulfurase and donate electrons for iron-sulfur cluster biosynthesis. Biochemistry56(3), 487–499 (2017).
   PubMed Web of Science ®Google Scholar
• Tsvetkov P , CoyS, PetrovaBet al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science375(6586), 1254–1261 (2022).
   PubMed Web of Science ®Google Scholar
• Xu Q , LiuT, WangJ. Radiosensitization-related cuproptosis lncRNA signature in non-small cell lung cancer. Genes (Basel)13(11), 2080 (2022).
   PubMed Web of Science ®Google Scholar
• Li X , DaiZ, LiuJet al. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer. Front. Genet.13, 969856 (2022).
   PubMed Web of Science ®Google Scholar
• Chen G , ZhangJ, TengW, LuoY, JiX. FDX1 inhibits thyroid cancer malignant progression by inducing cuprotosis. Heliyon9(8), e18655 (2023).
   PubMed Web of Science ®Google Scholar
• Lu H , LiangJ, HeXet al. A novel oncogenic role of FDX1 in human melanoma related to PD-L1 immune checkpoint. Int. J. Mol. Sci.24(11), 9182 (2023).
   PubMed Web of Science ®Google Scholar
• Dreishpoon MB , BickNR, PetrovaBet al. FDX1 regulates cellular protein lipoylation through direct binding to LIAS. J. Biol. Chem.299(9), 105046 (2023).
   PubMed Web of Science ®Google Scholar
• Olivieri F , PrattichizzoF, GiulianiAet al. miR-21 and miR-146a: the microRNAs of inflammaging and age-related diseases. Ageing Res. Rev.70, 101374 (2021).
   PubMed Web of Science ®Google Scholar
• Bautista-Sanchez D , Arriaga-CanonC, Pedroza-TorresAet al. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics. Mol. Ther. Nucleic Acids20, 409–420 (2020).
   PubMedGoogle Scholar
• Bica-Pop C , Cojocneanu-PetricR, MagdoL, RadulyL, GuleiD, Berindan-NeagoeI. Overview upon miR-21 in lung cancer: focus on NSCLC. Cell. Mol. Life Sci.75(19), 3539–3551 (2018).
   PubMed Web of Science ®Google Scholar
• Zhan Y , ChenZ, LiYet al. Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA. J. Exp. Clin. Cancer Res.37(1), 273 (2018).
   PubMedGoogle Scholar
• Wang P , ChenD, MaH, LiY. LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis. Onco Targets Ther.10, 5137–5149 (2017).
   PubMed Web of Science ®Google Scholar
• Kong B , LvZD, WangY, JinLY, DingL, YangZC. Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer. Int. J. Clin. Exp. Pathol.8(9), 11076–11083 (2015).
   PubMed Web of Science ®Google Scholar
• Cao Y , LiY, ZhangNet al. Quantitative DNA hypomethylation of ligand Jagged1 and receptor Notch1 signifies occurrence and progression of breast carcinoma. Am. J. Cancer Res.5(6), 1897–1910 (2015).
   PubMed Web of Science ®Google Scholar
• Xu S , YueY, ZhangSet al. STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1/MUC1 pathway. J. Exp. Clin. Cancer Res.37(1), 305 (2018).
   PubMedGoogle Scholar
• Han J , WangJZ, YangXet al. METTL3 promotes tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in an m6A-dependent manner. Mol. Cancer18(1), 110 (2019).
   PubMed Web of Science ®Google Scholar
• Peng W , LiJ, ChenRet al. Upregulated METTL3 promotes metastasis of colorectal cancer via miR-1246/SPRED2/MAPK signaling pathway. J. Exp. Clin. Cancer Res.38(1), 393 (2019).
   PubMed Web of Science ®Google Scholar
• Kim JH , AhnJH, LeeM. Upregulation of microRNA-1246 is associated with BRAF inhibitor resistance in melanoma cells with mutant BRAF. Cancer Res. Treat.49(4), 947–959 (2017).
   PubMed Web of Science ®Google Scholar
• Chang L , GuoR, YuanZ, ShiH, ZhangD. LncRNA HOTAIR regulates CCND1 and CCND2 expression by sponging miR-206 in ovarian cancer. Cell Physiol. Biochem.49(4), 1289–1303 (2018).
   PubMedGoogle Scholar
• Salem M , ShanY, BernaudoS, PengC. miR-590-3p targets cyclin G2 and FOXO3 to promote ovarian cancer cell proliferation, invasion, and spheroid formation. Int. J. Mol. Sci.20(8), 1810 (2019).
   PubMed Web of Science ®Google Scholar
• Lin S , LiuJ, JiangWet al. METTL3 promotes the proliferation and mobility of gastric cancer cells. Open Med. (Wars.)14, 25–31 (2019).
   PubMedGoogle Scholar
• Wei W , HuoB, ShiX. miR-600 inhibits lung cancer via downregulating the expression of METTL3. Cancer Manag. Res.11, 1177–1187 (2019).
   PubMed Web of Science ®Google Scholar
• Yan H , LiH, LiPet al. Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis. J. Exp. Clin. Cancer Res.37(1), 237 (2018).
   PubMedGoogle Scholar
• Chen Q , ZhangJ, HeY, WangY. hsa_circ_0061140 knockdown reverses FOXM1-mediated cell growth and metastasis in ovarian cancer through miR-370 sponge activity. Mol. Ther. Nucleic Acids13, 55–63 (2018).
   PubMedGoogle Scholar
• Sheng N , XuYZ, XiQHet al. Overexpression of KIF2A is suppressed by miR-206 and associated with poor prognosis in ovarian cancer. Cell Physiol. Biochem.50(3), 810–822 (2018).
   PubMedGoogle Scholar
• Tang X , ZengX, HuangYet al. miR-423-5p serves as a diagnostic indicator and inhibits the proliferation and invasion of ovarian cancer. Exp. Ther. Med.15(6), 4723–4730 (2018).
   PubMed Web of Science ®Google Scholar
• Yuan L , LiS, ZhouQet al. MiR-124 inhibits invasion and induces apoptosis of ovarian cancer cells by targeting programmed cell death 6. Oncol. Lett.14(6), 7311–7317 (2017).
   PubMed Web of Science ®Google Scholar
• Lai XJ , ChengHF. LncRNA colon cancer-associated transcript 1 (CCAT1) promotes proliferation and metastasis of ovarian cancer via miR-1290. Eur. Rev. Med. Pharmacol. Sci.22(2), 322–328 (2018).
   PubMed Web of Science ®Google Scholar
• Yang Z , LiJ, FengGet al. MicroRNA-145 modulates N(6)-methyladenosine levels by targeting the 3′-untranslated mRNA region of the N(6)-methyladenosine binding YTH domain family 2 protein. J. Biol. Chem.292(9), 3614–3623 (2017).
   PubMed Web of Science ®Google Scholar
• Yue B , SongC, YangLet al. METTL3-mediated N6-methyladenosine modification is critical for epithelial–mesenchymal transition and metastasis of gastric cancer. Mol. Cancer18(1), 142 (2019).
   PubMed Web of Science ®Google Scholar
• Li T , HuPS, ZuoZet al. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol. Cancer18(1), 112 (2019).
   PubMed Web of Science ®Google Scholar
• Yang F , JinH, QueBet al. Dynamic m(6)A mRNA methylation reveals the role of METTL3-m(6)A-CDCP1 signaling axis in chemical carcinogenesis. Oncogene38(24), 4755–4772 (2019).
   PubMed Web of Science ®Google Scholar
• Wang H , DengQ, LvZet al. N6-methyladenosine induced miR-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1. Mol. Cancer18(1), 181 (2019).
   PubMed Web of Science ®Google Scholar
• Zhou Z , WangP, SunRet al. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. J. Immunother. Cancer9(3), e001946 (2021).
   PubMed Web of Science ®Google Scholar
• Diggs LP , RufB, MaCet al. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. J. Hepatol.74(5), 1145–1154 (2021).
   PubMed Web of Science ®Google Scholar
• Li Y , GuJ, XuFet al. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma. Brief. Bioinform.22(4), (2021).
   Web of Science ®Google Scholar
• Chen M , WeiL, LawCTet al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology67(6), 2254–2270 (2018).
   PubMed Web of Science ®Google Scholar
• Hua W , ZhaoY, JinXet al. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol. Oncol.151(2), 356–365 (2018).
   PubMed Web of Science ®Google Scholar
• Ye K , LiL, WuB, WangD. METTL3 m6A-dependently promotes miR-21-5p maturation to accelerate choriocarcinoma progression via the HIF1AN-induced inactivation of the HIF1A/VEGF pathway. Genes Genomics44(11), 1311–1322 (2022).
   PubMed Web of Science ®Google Scholar
• Bernaudo S , SalemM, QiXet al. Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/beta-catenin signaling. Oncogene35(36), 4816–4827 (2016).
   PubMed Web of Science ®Google Scholar
• Xue L , LiJ, LinYet al. m(6) A transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer. J. Cell. Physiol.236(4), 2649–2658 (2021).
   PubMed Web of Science ®Google Scholar
• Li M , WangQ, ZhangX, YanN, LiX. CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p. Cell Cycle20(13), 1279–1294 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang Y , LiuS, ZhaoT, DangC. METTL3-mediated m6A modification of Bcl-2 mRNA promotes non-small cell lung cancer progression. Oncol. Rep.46(2), 163 (2021).
   PubMed Web of Science ®Google Scholar
• Dou X , WangZ, LuW, MiaoL, ZhaoY. Correction: METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a m6A-YTHDF1 dependent way. BMC Pulm. Med.22(1), 450 (2022).
   PubMed Web of Science ®Google Scholar
• Shi L , GongY, ZhuoL, WangS, ChenS, KeB. Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer. Ann. Transl. Med.10(3), 139 (2022).
   PubMed Web of Science ®Google Scholar
• Huang S , LuoS, GongCet al. MTTL3 upregulates microRNA-1246 to promote occurrence and progression of NSCLC via targeting paternally expressed gene 3. Mol. Ther. Nucleic Acids24, 542–553 (2021).
   PubMedGoogle Scholar
• Xie M , ChengB, YuSet al. Cuproptosis-related MiR-21-5p/FDX1 axis in clear cell renal cell carcinoma and its potential impact on tumor microenvironment. Cells12(1), 173 (2022).
   PubMed Web of Science ®Google Scholar
• Cao Y , DiX, CongSet al. RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC. Life Sci.315, 121359 (2023).
   PubMed Web of Science ®Google Scholar
• Zhong J , RenX, ChenZet al. miR-21-5p promotes lung adenocarcinoma progression partially through targeting SET/TAF-Iα. Life Sci.231, 116539 (2019).
   PubMed Web of Science ®Google Scholar